Circulating tumor cells are specific cells that shed from the body's solid tumor and then enter the blood circulation. The progress and therapeutic effects of the disease can be easily assessed by detecting the number of circulating tumor cells. The Cell Search system automatically detects and counts circulating tumor cells, making it the standard for a new class of diagnostic tools. The system's specificity, sensitivity, and reproducibility ensure that it can perform a series of tests on circulating tumor cells during the first treatment cycle to assess disease progression. The test used an antibody that binds to fine iron particles, also known as iron. These antibody/iron complexes specifically bind to circulating tumor cells, and their powerful magnetic field then “pulls†the circulating tumor cells into blood samples, and then stains with additional biomolecules and chemicals, and the circulating tumor cells can be clearly identified. . Compared to existing standard therapies, the Cell Search test can be used long before traditional imaging (such as CT scans) and there are no common variations like other blood tests (aka serum tumor markers). For a validation requirement for Cell Search amplification approval, the vendor conducted a prospective and multicenter clinical study involving 55 clinical centers in the US and Europe, recruiting 430 metastatic junctions that are undergoing first or second line treatment. Patients with rectal cancer. The data showed that patients with baseline values ​​of less than 3 cycles of tumor cells were significantly better than patients with more than 3 circulating tumor cells. The overall finding is consistent with the situation in patients with metastatic breast cancer. The data also show that circulating tumor cells can reliably and independently predict progression-free survival and overall survival. Combining circulating tumor cell analysis with radiology may be the most accurate assessment of prognosis. The CellSearch® Circulating Tumor Cell (CTC) test is a simple blood test that captures and evaluates circulating tumor cells at any time to determine the prognosis of patients with metastatic breast, colorectal or prostate cancer. Detection provides objective quantitative, real-time reading information, so oncologists can provide patients with the best treatment options. HEBEI PINGLE FLOUR MACHINERY GROUP CO., LTD , https://www.plrollermill.com